Investor Overview

Satsuma Pharmaceuticals Investor Relations

 

Recent News
Jul 28, 2021
Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

South San Francisco, CA, July 28, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine...

Jun 22, 2021
Satsuma Pharmaceuticals to Present at SVB Leerink’s CNS Forum

June 22, 2021 South San Francisco, CA, June 22, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal...

Jun 16, 2021
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths

South San Francisco, CA, June 16, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...

Stock Info
NASDAQSTSA